Strategy for the Application of Therapy in Prostate Cancer

  • Christopher J. Logothetis
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 617)

The rational application of integrated multidisciplinary therapy of prostate cancer (PC) requires an understanding of the determinants of cancer progression and response to therapy to successfully treat common adult cancers. In the successful examples of therapy application agents (chemotherapy, biologics) and other modalities (radiation, surgery) are applied on the basis of clinical biology during specific intervals in progression. Thus integrating the knowledge of clinical biology with an appreciation for the determinants is central to therapy development.


Prostate Cancer Gleason Score Serum Vascular Endothelial Growth Factor Prostate Cancer Progression Androgen Ablation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Scher HI, Mazumdar M, Kelly WK (1996) Clinical trials in relapsed prostatcancer: Defining the target. J Natl Cancer Inst 88:1623–1634.PubMedCrossRefGoogle Scholar
  2. 2.
    Logothetis CJ (2003) The case for a biologically based classification of prostate cancer. Semin Oncol 30:562–566.PubMedCrossRefGoogle Scholar
  3. 3.
    Lee WH, Isaacs WB, Bova GS, et al. (1997) CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: A new prostate cancer biomarker. Cancer Epidemiol Biomarkers Prev 6:443–450.PubMedGoogle Scholar
  4. 4.
    Nelson WG, DeWeese TL, De Marzo AM, et al. (2002) Prostate cancer prevention, in Kantoff PW, Carroll PR, D’Amico AW (eds): Prostate Cancer: Principles and Practice. Philadelphia, PA, Lippincott Williams & Wilkins, pp. 67–72.Google Scholar
  5. 5.
    Mohan S, Baylink DJ (1991) Bone growth factors. Clin Orthop 263:30–48.PubMedGoogle Scholar
  6. 6.
    Whitmore Willet F (1990) Natural history of low-stage prostatic cancer and the impact of early detection. Urol Clin North Am 17:689–697.Google Scholar
  7. 7.
    Strom SS, Wang X, Pettaway CA, Logothetis CJ, et al. (2005) Obesity, weight gain and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 11:6889–6894.PubMedCrossRefGoogle Scholar
  8. 8.
    Harlan L, Brawley O, Pommerenke F, et al. (1995) Geographic, age and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol 13:93–100.PubMedGoogle Scholar
  9. 9.
    De Marzo AM, Marchi VL, Epstein JI, et al. (1999) Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol 155:1985–1992.PubMedGoogle Scholar
  10. 10.
    Kim J*, Sun P*, Troncoso P, Sabichi AL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lam YW, Lippman SM, McDonnell TJ, Lieberman R, Mobley JA, Logothetis CJ, Ho SM. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer (*co-first authors) (2005) Cancer Epidemiol Biomarkers Prev 14:1697–1702.PubMedCrossRefGoogle Scholar
  11. 11.
    Partin AW, Yoo J, Carter B, et al. (1993) The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol I50:110–114.Google Scholar
  12. 12.
    Kattan MW, Stapleton AM, Wheeler TM, et al. (1997) Evaluation of a momogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 79:528–537.PubMedCrossRefGoogle Scholar
  13. 13.
    Di Sant’ Agnese PA (1992) Neuroendocrine differentiation in carcinoma of the prostate: Diagnostic, prognostic, and therapeutic implications. Cancer 70:254–268.CrossRefGoogle Scholar
  14. 14.
    Pound CR, Partin AW, Eisenberger MA, et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591–1597.PubMedCrossRefGoogle Scholar
  15. 15.
    Ellerhorst JA, Tu SM, Amato RJ, et al. (1997) Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3:2371–2376.PubMedGoogle Scholar
  16. 16.
    Millikan RE, Baez L, Banerjee T, et al. (2001) Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen-independent prostate cancer. Urol Concol 6:111–115.CrossRefGoogle Scholar
  17. 17.
    Glotzman D (1997) Mechanisms of the development of osteoblastic metastasis. Cancer 80:1581–1587 (suppl).CrossRefGoogle Scholar
  18. 18.
    Navone NM, Labate ME, Troncoso P, et al. (1999) p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 161:304–308.PubMedCrossRefGoogle Scholar
  19. 19.
    Antwerp DJV, Martin SJ, Kafri T, et al. (1996) Suppression of the TNFα-induced apoptosis by NFκB. Nature 274:787–789.Google Scholar
  20. 20.
    McDonnell TJ, Troncoso P, Brishay SM, et al. (1992) Expression of the proto-oncogene bcl-2 in the prostate and its association with the emergence of androgen-independent prostate cancer. Cancer Res 52:6940–6944.PubMedGoogle Scholar
  21. 21.
    Macoska JA, Trybus TM, Sakr WA, et al. (1994) Fluorescence in situ hybridization analysis of pallelic loss and chromosomal instability in human prostate cancer. Cancer Res 54:3824–3830.PubMedGoogle Scholar
  22. 22.
    Tu SM, Millikan RE, Mengistu B, et al. (2001) Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomized phase II trial. Lancet 357:336–341.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Christopher J. Logothetis
    • 1
  1. 1.Department of GU Medical Oncology UTMD Anderson Cancer CenterHoustonUSA

Personalised recommendations